272105-42-7
272105-42-7 結(jié)構(gòu)式
基本信息
地司特泰
TGF-Β1抑制劑(DISITERTIDE)
L-蘇氨酰-L-絲氨酰-L-亮氨酰-L-ALPHA-天冬氨酰-L-丙氨酰-L-絲氨酰-L-異亮氨酰-L-異亮氨酰-L-色氨酰-L-丙氨酰-L-蛋氨酰-L-蛋氨酰-L-谷氨酰胺酰-L-天冬酰胺
P144 Peptide
TSLDASIIWAMMQN
P144
P144 PEPTIDE
DISITERTIDE, >98%
Disitertide,P144,P144 Peptide, >98%
L-Asparagine, L-threonyl-L-seryl-L-leucyl-L-α-aspartyl-L-alanyl-L-seryl-L-isoleucyl-L-isoleucyl-L-tryptophyl-L-alanyl-L-methionyl-L-methionyl-L-glutaminyl-
L-Threonyl-L-seryl-L-leucyl-L-alpha-aspartyl-L-alanyl-L-seryl-L-isoleucyl-L-isoleucyl-L-tryptophyl-L-alanyl-L-methionyl-L-methionyl-L-glutaminyl-L-asparagine
物理化學(xué)性質(zhì)
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2022/09/18 | HY-P0118 | 地司特泰 Disitertide | 272105-42-7 | 5mg | 3500元 |
| 2022/09/18 | HY-P0118 | 地司特泰 Disitertide | 272105-42-7 | 10mg | 5600元 |
| 2022/09/18 | HY-P0118 | 地司特泰 Disitertide | 272105-42-7 | 25mg | 11500元 |
常見問題列表
Disitertide (100 μg/mL) suppresses the protein expression levels of PI3K and p-Akt, and induce the protein expression of Bax in MC3T3-E1 cells.
Disitertide (TGF-β1 inhibitor) abrogates the MACC1- AS1 expression in GC cells, suggesting that targeting TGFβ signaling pathway may be a potential strategy to inhibit MSC-induced stemness and chemoresistance.
Disitertide (P144, 10 μg/mL to 200 μg/mL) affects proliferation, induces apoptosis as well as anoikis in A172 and U-87 MG GBM cell lines.
Western Blot Analysis
| Cell Line: | Mouse embryo osteoblast precursor MC3T3-E1 cells. |
| Concentration: | 100 μg/mL. |
| Incubation Time: | 4 h. |
| Result: | Significantly suppressed the protein expression levels of PI3K and p-Akt, and induce the protein expression of Bax in MC3T3-E1 cells compared with the miR-590 group. |
Disitertide (Topical application, 300 μg/mL) may promote scar maturation and clinical improvement of hypertrophic scar morphology features in an “in vivo” model in nude mice after two weeks of treatment.
| Animal Model: |
Human hypertrophic scars were implanted in 60 nude mice.
|
| Dosage: | 300 μg/mL was added the Lipogel. |
| Administration: | Topical application daily administered. |
| Result: | Successful shedding was achieved in 83,3% of the xenografts. |